The survival rates of brain cancer in mice treated with anti-CTLA-4 and anti-PD-1 monotherapy were 40% and 60%, respectively, whereas the survival rate was up to 78% when the two were combined [31]. The gene discussed is CTLA4; the disease is brain cancer.